GABAeron Presents Promising Preclinical Data on Stem Cell-Based Therapy for Alzheimer’s Disease

SAN FRANCISCO: SAN FRANCISCO, Oct. 27, 2021 /PRNewswire/ -- GABAeron, Inc. today presented promising preclinical data on their first-in-class, iPSC-based cell therapy product for Alzheimer's disease at the International Society for Stem Cell Research (ISSCR) and Japanese Society for Regenerative Medicine (JSRM) international meeting "Stem Cells: From Basic Science to...

Click to view original post